Related Experiment Video
Updated: May 1, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
Anti-inflammatory effects of diethylcarbamazine: a review
Christina Alves Peixoto1, Bruna Santos Silva1
1Laboratório de Ultraestrutura, Centro de Pesquisas Aggeu Magalhães, Fundação Oswaldo Cruz, Cidade Universitária, Av. Moraes Rego s/n, Recife CEP 50670-420, PE, Brazil.
Abstract:
Diethylcarbamazine (DEC) interferes with cyclooxygenase and lipoxygenase pathways, reducing the production of thromboxane, prostacyclin, prostaglandin and leukotrienes. Recent studies using different experimental models of inflammation have indicated that DEC, in addition to inhibiting cyclooxygenase and lipoxygenase pathways, also inhibits nuclear transcription factor kappa B (NF-κB) activation, which is a key regulator of proinflammatory genes such as TNF-α, IL-1β, inducible nitric oxide synthase (iNOS) and even cyclooxygenase 2 (COX-2). The aim of the present study is to provide a comprehensive summary of DEC, including a description of filaricidal action, inhibition of synthesis and secretory pathways, immunomodulatory activity, and specific inhibition of lipoxygenase and cyclooxygenase pathways.
Related Concept Videos
Anthelminthic Agents
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Drugs for Treatment of Ulcerative Colitis in IBD
Carboxylic Acids to Methylesters: Alkylation using Diazomethane

